Navigation Links
FROST Clinical Study for Nonsurgical Treatment of Early Stage Breast Cancer Recruiting Patients
Date:9/5/2017

Sanarus Technologies, developers of the Visica® 2 Treatment System, is currently enrolling patients for the FROST clinical study, “Freezing Alone Instead of Resection Of Small Breast Tumors: A Study of Cryoablation in the Management of Early Stage Breast Cancer.” The FROST study is a phase II single-arm multicenter clinical trial that examines the use of cryoablation as an alternative to surgical resection for the management of primary early stage invasive breast cancer.

Cryoablation, also called percutaneous cryotherapy, is a minimally invasive treatment that uses extreme cold to destroy diseased tissue, including cancer cells. During breast cryoablation with the Visica 2 Treatment System, a hollow-tipped probe is placed into the tumor under ultrasound guidance. Liquid nitrogen passes through the probe and forms an ice ball around the lesion in a closed-loop system. The intense cold freezes the tumor, causing cell destruction. The procedure generally takes about 30 minutes and is done under local anesthesia in a physician’s office or outpatient setting. Cryoablation is often used to treat skin conditions, as well as tumors in the lungs, kidneys, prostate and liver. The primary goal of the FROST study is to determine the rate of complete tumor ablation (destruction) and absence of residual breast carcinoma as a result of treatment with cryoablation alone.

Breast cryoablation has already been shown to be a safe and effective minimally invasive alternative to lumpectomy in earlier studies. The current clinical study is a follow-up to the landmark National Cancer Institute-sponsored study “ACOSOG (Alliance) Z1072” trial which showed 100% ablation success in all breast tumors less than 1.0 cm and was effective in 92% of all targeted tumors. The Visica 2 Treatment System was the exclusive device used in the Z1072 study.

FROST investigators are actively recruiting 200 female patients, 50+ years of age, at 20 locations nationwide. The study will track the breast tumor recurrence rates, assess breast cosmesis post-treatment, record adverse events and provide 5-year follow-up. To date, nine centers are participating in the study, with 50 centers requesting inclusion in the 11 slots remaining. Patient eligibility requirements include unifocal primary invasive breast cancer diagnosed by core needle biopsy; maximum tumor size less than or equal to 1.5 cmI; adequate breast size with 0.5 cm margins between the ablated lesion and the skin; tumor distance greater than 3mm from the chest wall or muscle. Cryoablation will be done with the Visica 2 Treatment System.

“Cryoablation is a very promising alternative to traditional surgery for early stage breast cancer,” said Dennis R. Holmes, M.D., FACS, lead investigator of the FROST study. “Cryoablation minimizes changes in breast volume and nipple position, avoids prominent scars, and eliminates many of the side effects of breast cancer surgery. The outstanding results of Z1072 inspired me to start the FROST clinical study, which will eliminate the need for surgery for many women with early stage breast cancer.”

Currently, the standard of care for early stage breast cancer is surgery and sentinel node biopsy, followed by radiotherapy and endocrine and/or chemotherapy. Cryoablation is a minimally invasive alternative to lumpectomy that can destroy early stage tumors, often mitigating the need for adjuvant treatment. In addition, preliminary studies suggest that cryoablation may initiate an anti-cancer immune response, leading to a reduction in the rate of recurrence. After treatment with cryoablation, there is virtually no scarring or disfigurement of the breast. Discomfort following the procedure is mild, with most patients resuming normal activity relatively quickly.

“Less is more with cryoablation of breast cancers,” said Dr. Michael Plaza, breast radiologist and FROST trial investigator at the Diagnostic Center for Women in Miami. “This study is an important step that may lead to a new era in which we treat early stage breast cancer with minimally invasive cryoablation, rather than lumpectomy or mastectomy. We hope that cryoablation will prove to be as effective as surgery, but without the need for general anesthesia and prolonged recovery time.”

To find out more about the FROST clinical study, visit clinicaltrials.gov. To find a physician who specializes in this procedure, contact Sanarus Technologies at 800-909-3060 or send an email to: support@sanarus.com.

About Sanarus Technologies 
In 2001, the Visica® 2 Treatment System was the first device available for cryoablation of fibroadenomas. Since then, our system has been used to successfully treat thousands of patients. The Visica 2 Treatment System is FDA-cleared for the ablation of cancerous or malignant tissue and benign tumors. At Sanarus, we develop innovative solutions for the nonsurgical treatment of breast tumors. We are headquartered in Pleasanton, CA, and all our products are manufactured in the USA. Find out more at http://www.sanarus.com.

Read the full story at http://www.prweb.com/releases/2017/09/prweb14650914.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. National Association of Professional Women Announces Judy Frost, Business Manager of Midwest Pathology Associations, LLC, as VIP Woman of the Year
2. Beer Frost is a Cooler’s Perfect Companion
3. Ice Dams and Frozen Pipes: Amica Shares Tips to Prepare for the Frosty Months
4. Article on Singer and Model Jenny Frost’s Health Emphasizes Special Needs of Women with Hernias, Notes Beverly Hills Hernia Center
5. Frost Miller Tapped for Crohn’s and Colitis CongressTM Promotion
6. Kidney Week 2013: New innovations in clinical science
7. Salar Joins Medical Informatics Experts to Judge AMIA’s First Ever Student Design Challenge: Reinventing Clinical Documentation
8. The DelRay Recovery Center Appoints Britt Bonner as the Director of Clinical Outreach
9. Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow
10. Nemours receives Dept. of Defense award to study physicians maintenance of optimal clinical program
11. Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which ... evacuation of the facility as part of a disaster drill on October 3rd. , ... and Shelton City Emergency Manager, as well as the Connecticut Long Term Care ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
Breaking Medicine Technology: